{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Azcarate-Peril MA"],"funding":["NIDDK NIH HHS","UNC Nutrition Obesity Research Center"],"pagination":["1957536"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8354614"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(1)"],"pubmed_abstract":["<b>Background</b>. Our recent publication (Chey et al., Nutrients 2020) showed that a 30-day administration of pure galacto-oligosaccharides (GOS) significantly reduced symptoms and altered the fecal microbiome in patients with lactose intolerance (LI). <b>Results</b>. In this addendum, we performed an in-depth analysis of the fecal microbiome of the 377 LI patients randomized to one of two GOS doses (Low, 10-15 grams/day or High, 15-20 grams/day), or placebo in a multi-center, double-blinded, placebo-controlled trial. Sequencing of 16S rRNA amplicons was done on GOS or placebo groups at weeks zero (baseline), four (end of treatment), nine, 16 and 22. Taxa impacted by treatment and subsequent dairy consumption included lactose-fermenting species of <i>Bifidobacterium, Lactobacillus, Lactoc"],"journal":["Gut microbes"],"pubmed_title":["A double-blind, 377-subject randomized study identifies <i>Ruminococcus, Coprococcus, Christensenella</i>, and <i>Collinsella</i> as long-term potential key players in the modulation of the gut microbiome of lactose intolerant individuals by galacto-oligosaccharides."],"pmcid":["PMC8354614"],"funding_grant_id":["P30 DK056350","P30 DK034987"],"pubmed_authors":["Azcarate-Peril MA","Chey WD","Marsh A","Savaiano DA","Sandborn WJ","Ritter AJ","Klaenhammer TR","Roach J"],"additional_accession":[]},"is_claimable":false,"name":"A double-blind, 377-subject randomized study identifies <i>Ruminococcus, Coprococcus, Christensenella</i>, and <i>Collinsella</i> as long-term potential key players in the modulation of the gut microbiome of lactose intolerant individuals by galacto-oligosaccharides.","description":"<b>Background</b>. Our recent publication (Chey et al., Nutrients 2020) showed that a 30-day administration of pure galacto-oligosaccharides (GOS) significantly reduced symptoms and altered the fecal microbiome in patients with lactose intolerance (LI). <b>Results</b>. In this addendum, we performed an in-depth analysis of the fecal microbiome of the 377 LI patients randomized to one of two GOS doses (Low, 10-15 grams/day or High, 15-20 grams/day), or placebo in a multi-center, double-blinded, placebo-controlled trial. Sequencing of 16S rRNA amplicons was done on GOS or placebo groups at weeks zero (baseline), four (end of treatment), nine, 16 and 22. Taxa impacted by treatment and subsequent dairy consumption included lactose-fermenting species of <i>Bifidobacterium, Lactobacillus, Lactoc","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jan-Dec","modification":"2026-04-08T08:21:55.16Z","creation":"2022-02-11T07:03:55.597Z"},"accession":"S-EPMC8354614","cross_references":{"pubmed":["34365905"],"doi":["10.1080/19490976.2021.1957536"]}}